ABSTRACT OBJECTIVES This report relates the authors' ongoing experience with percutaneous left ventricular (LV) unloading by using a transaortic LV assist device in combination with venoarterial extracorporeal membrane oxygenation (VA-ECMO) and provides an in-depth analysis of the hemodynamic benefit of this approach.
To avoid these complications, an LV venting strategy should be used. The authors recently
proposed the use of a percutaneous, retrograde, and transaortic LV assist device (Impella, Abiomed, Danvers, Massachusetts) to achieve LV unloading during VA-ECMO support. This strategy was termed "ECMELLA" (4) . The Impella is a percutaneously deployed, microaxial flow pump which pumps blood from the LV to the aortic root, thus reducing LV afterload and consecutively decreasing LV enddiastolic and pulmonary venous pressures (5) . Using a propensity-matched analysis, a mortality reduction and superiority of other outcome measurements were shown in patients treated with ECMELLA compared to that in patients treated with VA-ECMO alone (4).
The current study reviews the pathophysiology and reports the authors' ongoing experience with the ECMELLA approach for treatment of severe cardiogenic shock.
METHODS
The present study follows tenets of the Declaration of Helsinki and was approved by the local ethics committee.
STUDY DESIGN. We report outcomes for all consecutive patients who were treated with VA-ECMO in combination with Impella (ECMELLA) at our institution. Laboratory and clinical data were collected following a standardized protocol and entered into a dedicated database. In addition to the mechanical circulatory support strategy described below, all patients received optimal medical therapy in accordance with guidelines and local practice.
MECHANICAL CIRCULATORY SUPPORT STRATEGY.
The technical aspects of the ECMELLA approach have been described previously (4) . Briefly, both VA-ECMO and the Impella (Impella CP or Impella 2.5) are implanted percutaneously in contralateral femoral arteries. After implantation of both devices, patients were transferred to our cardiovascular intensive care unit. Chest radiography or echocardiography was performed at least once per day to assess device position.
The Impella was repositioned as needed to ensure the inflow port was approximately 4 cm below the aortic valve and that the outflow port was above the aortic valve as recommended by the manufacturer. Targeted VA-ECMO flow was 5 l/min for at least the first 24 h depending on the patient's need. Impella rotational speed was titrated up to achieve best unloading of the LV as assessed by echocardiography. There was no mandatory protocol for sedation or mechanical ventilation. The aim was to achieve the patient's spontaneous breathing and a conscious state as soon as possible. General medical treatment with inotropes and other supportive therapies was performed according to clinical needs based on current guidelines.
In case of hemodynamic stabilization (i.e., normalization of lactate levels and improvement of LV function on echocardiography), VA-ECMO flow was progressively reduced, and the patients were weaned as soon as possible. During weaning from VA-ECMO, the Impella support was increased to support the patient's blood pressure and cardiac output as needed.
Inotropes were reduced to a minimum in this period, if possible. After successful weaning from VA-ECMO, the patient was weaned from the Impella through a stepwise reduction of Impella flow. In case of severe myocardial dysfunction without signs of recovery during the initial 5 to 7 days, the transition from a femoral access Impella CP or 2.5 to a subclavian access Detailed baseline characteristics are summarized in Table 1 . During the study period, there were 5 cases in which implantation of a transaortic LV assist device in addition to VA-ECMO was intended but could not be performed (2 cases of severe peripheral artery disease, 2 cases of severe aortic valve stenosis, 1 case of aortic valve endocarditis).
IMPLANTATION CHARACTERISTICS AND CLINICAL
COURSE. In 60.3% of the cases, VA-ECMO and Impella were implanted simultaneously during the index procedure. This group of patients represents a cohort with severe cardiogenic shock and impaired LV function; 59.4% of these patients were cases of eCPR. In 20.8% of the cases, the Impella was the first device implanted with a staged VA-ECMO implantation. These patients were initially deemed to be sufficiently treated using only a transaortic LV assist device strategy. However, these patients deteriorated and were upgraded to ECMELLA. In the remaining 18.9% of patients, VA-ECMO was the first device implanted, followed by a staged Impella implantation. These patients either received VA-ECMO implantation at another hospital or were later upgraded with a transaortic LV assist device at our institution (35.0%). In the remaining patients, Impella implantation was delayed because of urgently needed diagnostics or interventions after VA-ECMO implantation ( Table 2 ).
An Impella CP was used in 78.3% of the cases. Upon implantation of the VA-ECMO, the median SAVE score was À12.5 (1st, 3rd quartile: À17.0, À8.0), and the median SAPS-II score was 81.0 (1st quartile, 3rd quartile: 74.0, 88.6), indicating a survival rate of 20% and 6.9%, respectively. Right-heart catheterization data were available from 3 patients during the index procedure.
Original tracings from 1 patient shows that pulmonary capillary wedge pressure (PCWP) increased above its already high level with the initiation of VA-ECMO support. With the addition of Impella, PCWP decreased rapidly (Figure 1) . Similar PCWP reductions were noted in all 3 patients for which data were available. Overall, lactate levels were slightly lower in survivors ( Figure 2) . The median duration of VA-ECMO support was 6.0 (1st, 3rd quartile: 3.0, 10.1) days with a median duration of Impella support of 6.0 (1st, 3rd quartile: 2.7, 12.0) days. OUTCOME AND COMPLICATIONS. Successful weaning from VA-ECMO support was achieved in 51.9% of the patients. In 12 patients (22%), an upgrade from an Impella CP to an Impella 5.0 was necessary to wean from VA-ECMO. Of these 12 patients, 5 received implants with a durable LV assist device, whereas the other 7 patients could be weaned from Impella 5.0.
Among the remaining patients successfully weaned from VA-ECMO, 7 underwent direct implantation with a durable LV assist device. There were no heart transplantations in the overall cohort. Weaning from VA-ECMO was less often observed after eCPR (35.3% vs. 67.3%, respectively; p < 0.01). The 30-day allcause mortality in the overall cohort was 64.2%, with a significantly higher mortality rate in patients with eCPR ( Figure 3) . Overall survival was higher (35.8%) than predicted by either the SAVE or SAPS-II score. Patients not weaned from VA-ECMO had a significantly higher rate of 30-day all-cause mortality than those who were successfully weaned from VA-ECMO (98.0% vs. 32.7%, respectively; p < 0.01).
Although there was a high incidence of vascular complications and bleedings requiring an intervention, both complications were equally divided among survivors and nonsurvivors. Hypoxic brain damage was more often prevalent in nonsurvivors, whereas sepsis was significantly more often present in survivors. There was a trend toward a higher incidence of stroke, abdominal compartment, mesenteric ischemia, and hemolysis among nonsurvivors. Detailed data for complications are displayed in Table 3 .
DISCUSSION
The prime finding of this study was that addition of an Impella to VA-ECMO (ECMELLA) for treatment of severe cardiogenic shock was feasible for patients in an all-comers cohort. Although mortality remained high, the ECMELLA approach resulted in better survival rates as predicted by 2 different risk scores.
The principles underlying the impact of VA-ECMO on systemic hemodynamics, LV mechanics, and LV energetics are well documented (7), well appreciated in the clinical setting, and validated in preclinical studies (8) (Figure 4) . The fundamental issue with VA-ECMO alone is that venous return to the LV (through residual flow through the pulmonary circuit, venous return from the bronchial circulation, and Thebesian flow) must exit the LV through the aortic valve; however, the increased systemic flow provided by VA-ECMO and resultant increased blood pressure (both beneficial effects for oxygen delivery to the end organs) must be overcome by the weak LV. In patients with insufficient contractile reserve, LV preload, enddiastolic pressure, and thus PCWP increase until, through the Frank-Starling mechanism, LV stroke volume matches venous return to the LV (Figure 4) . Values are median (1st, 3rd quartile) or n (%). Characteristic of mechanical circulatory support in 30-day survivors and 30-day nonsurvivors of cardiogenic shock treated with Impella in addition to VA-ECMO.
Abbreviations are as in Table 1 . Therefore, the presented results may only be exploratory and hypothesis generating.
CONCLUSIONS
Implantation of a transaortic LV assist device in combination with VA-ECMO resulted in better outcome in an all-comers cohort than predicted by 2 established risk scores. We hypothesize that this relates to the reduction in LV filling pressures, which is supported by the underlying physiological principles.
Ultimately, a randomized, controlled trial comparing ECMELLA, conventional VA-ECMO, and Impella treatment is needed to further define the optimal approach in different patient subgroups.
